Teva closes $700m Emalex buy to add ecopipam for Tourette syndrome
Teva Pharmaceutical Industries has completed its acquisition of Emalex Biosciences, paying $700 million at closing with up to $200 million in additional commercial milestone payments and net sales-based royalties contingent on regulatory approval. The deal brings ecopipam — a selective dopamine D1 receptor antagonist in development for paediatric Tourette syndrome — into Teva's late-stage pipeline.
Phase 3 data for ecopipam were published in JAMA Neurology ahead of the deal closing. The pivotal study used a randomised withdrawal design, measuring time to relapse in paediatric patients who had stabilised on ecopipam before being rerandomised to either continued treatment or placebo. The study met its primary endpoint with statistical significance (p = 0.0084). The most commonly reported adverse events were somnolence (10.2%), insomnia (7.4%), anxiety (6.0%), fatigue (5.6%), and headache (5.1%). Teva said an NDA submission to the US Food and Drug Administration is anticipated in the second half of 2026, supported by the asset's existing Orphan Drug and Fast Track designations.
The strategic case
Richard Francis, Teva's president and chief executive, said the acquisition is consistent with the company's declared "Pivot to Growth" strategy, describing it as "focused, capital-efficient business development" that adds a late-stage opportunity in an area of significant unmet need. Ecopipam was developed by Emalex Biosciences, itself created by Chicago-based Paragon Biosciences to advance central nervous system therapies.
The D1 receptor mechanism distinguishes ecopipam from currently available treatments for Tourette syndrome. Existing options — primarily antipsychotics such as haloperidol and aripiprazole, as well as the VMAT2 inhibitors valbenazine and deutetrabenazine — work through different dopaminergic or vesicular pathways and carry tolerability burdens that limit their use in a predominantly paediatric population. A first-in-class D1 antagonist, if approved, could attract prescribers looking for a differentiated safety and efficacy profile, though head-to-head comparisons with approved agents have not been reported.
Market context and regulatory read-across
Tourette syndrome affects an estimated 1% of school-age children worldwide, though its Orphan Drug designation in the US reflects a treated population of 200,000 or fewer. For Teva, whose neuroscience franchise includes the CGRP antibody fremanezumab (Ajovy) and the long-established multiple sclerosis therapy Copaxone, ecopipam would add a paediatric rare-disease asset with a relatively clear regulatory path — Orphan and Fast Track designations together can support rolling NDA review and expedited FDA engagement.
The FDA has in recent years shown a willingness to accept time-to-relapse endpoints in rare neurological conditions, as seen in VMAT2 inhibitor approvals, which may support a straightforward review cycle for ecopipam. However, the NDA will need to address the somnolence signal observed in roughly one in ten patients, a concern that regulators scrutinise closely in paediatric label applications.
More broadly, the transaction is a capital-efficient bet by a company carrying significant debt. At $700 million upfront for a near-filed asset in a rare indication, Teva is paying for late-stage de-risking rather than early-platform optionality — a posture consistent with its stated shift away from early-stage discovery spending and towards in-licensing and acquisitions of programmes close to the finish line.